MedTech Business - May 6, 2026
Encare sets its sights on the USA
When Encare was awarded the Swecare Export Award 2026, the company was highlighted as one of the Swedish healthtech companies that has succeeded in translating clinical research into concrete benefits in healthcare internationally.
Business article - April 7, 2026
Zealand Pharma establishes US Research Hub in Cambridge
The new research hub in Cambridge, Massachusetts, in the greater Boston area, will serve as Zealand Pharma’s primary US address and is expected to be operational from September 2026.
New Market - April 7, 2026
Immedica announces first marketing authorization approval in the MENA region
Immedica has announced that the Kuwait Ministry of Health (MOH) has granted Marketing Authorization (MA) approval for Ztalmy (ganaxolone) for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in Kuwait.
MedTech Business - February 16, 2026
FDA grants De Novo Classification request from Amferia
Amferia's antibacterial wound dressing has been granted approval by the US Food and Drug Administration (FDA) through the De Novo Classification Request track, allowing Amferia to enter the US market with a unique Class 2 medical device antibacterial dressing for advanced wound care.
Biotech Business - February 2, 2026
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand
Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.
New Market - January 12, 2026
Novo Nordisk’s Wegovy pill now broadly available across America
Wegovy pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.